Fresenius Kabi, a global healthcare company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition, has signed an exclusive distribution agreement for the U.S. with Corvida Medical.
Under the terms of the agreement, Fresenius Kabi will be the exclusive U.S. distributor for the HALO Closed System Drug-Transfer Device (CSTD). The HALO system is an airtight and leak-proof CSTD that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, thereby minimizing individual and environmental exposure to drug vapor, aerosols and droplets. These are common challenges during the compounding and administration of hazardous drugs like chemotherapy.
“Fresenius Kabi is committed to offering solutions that provide the safe preparation and delivery of medications across the continuum of care,” says John Ducker, president and CEO of Fresenius Kabi USA. “CSTDs play a critical role in protecting healthcare professionals from the risks of exposure to hazardous drugs during the preparation in the pharmacy and during patient administration by nurses. The combination of Fresenius Kabi freeflex/freeflex+ IV solution containers, oncology medicines and Corvida Medical’s HALO CSTD allows Fresenius Kabi to provide customers a broad range of products to assist with their oncology needs.”
Mitch Moeller, CEO of Corvida Medical, also spoke out about the partnership, commenting: “We believe Fresenius Kabi is a great partner for the HALO Closed System Drug-Transfer Device. Their reputation for quality and patient focus, along with their commercial infrastructure, distribution experience, customer relationships and extensive product portfolio will help our efforts to make HALO a leading CSTD option for U.S. customers. We are pleased that Fresenius Kabi recognized the design benefits, innovation, and quality of the HALO product portfolio.”
The distribution agreement may be expanded to other territories in the future. Financial terms of the agreement were not disclosed.